The results of the annual government health insurance review were released today, and those with health insurance can expect an average increase of around 5.59%.

According to News Corp media, Medibank Private Ltd (ASX: MPL) will lift prices by an average of 5.64%, while Bupa and NIB Holdings Limited (ASX: NHF) will raise premiums by 5.69% and 5.55% respectively.

What does this mean for shareholders?

Medibank and NIB shareholders can look forward to another lift in revenues this year as a result of the price increases, which were higher than expected but reportedly lower than the insurers initially demanded.

Health insurers have enjoyed several years of ~6% annual increases in premiums, which reflect the rising cost of healthcare and an ageing population. Insurance is a lumpy business, and the revenue doesn’t necessarily come out as profit.

However, with an increased focus on reducing expenses and cutting waste from the healthcare system, reduced claim expenses as well as lower cost of procedures could well result in higher profits for insurers.

Great news, but…

The catch is that the affordability of health insurance is becoming critical for consumers. Health Minister Sussan Ley touted the 5.59% increase as a victory, given the reduction from insurers’ original claims which the Minister rejected.

However, half-a-million Australians downgraded or cancelled their health insurance in the last year – an estimated 5% of total individuals with insurance. With price reportedly a big consideration, funds might expect a continuing decline in customer numbers this year, as well as ongoing churn of customers changing insurers, looking for a better deal.

(As a side note, this could be a positive for insurance comparison website iSelect Ltd (ASX: ISU), which is currently running promotions to benefit from the premium rise).

So while today’s announcement appears to be good news for shareholders, it’s not that good. Investors will want to watch for further developments on customer numbers and churn, as well as an ongoing industry and government efforts to reign in healthcare expenditure, which is growing substantially faster than inflation.

Looking for reliable, growing dividends?

Discover these 3 "new breed" blue chips that pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to discover our latest free report on these three outstanding investment opportunities.

Simply click on the link, enter your email address, and we'll send you our full coverage for free - no credit card details or payment required!

What are you waiting for? Just click here now for your copy.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.